Accretion Nutraveda Limited Sets October 31 Results Meeting

Accretion Nutraveda Limited will hold a board meeting on October 31, 2026, to consider unaudited financial results for the half year ended September 30, 2026. The meeting follows FY26 revenue from operations of ₹33.60 crore, up 110% year-on-year, while net profit after tax rose 102.8% to ₹5.07 crore.

Why is Accretion Nutraveda holding a board meeting on October 31?

Accretion Nutraveda has informed BSE Limited that its board will meet on Saturday, October 31, 2026, to consider and approve unaudited financial results for the half year ended September 30, 2026. The intimation was reported on October 24, setting out the financial-results agenda for the meeting.

The planned disclosure is the company’s next reported financial update after its audited results for the year ended March 31, 2026. The board had met on May 8, 2026, to consider and approve those audited FY26 results. The company had informed BSE about that meeting on May 1 under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Accretion Nutraveda also announced on September 28 that its trading window would close from October 1. It will remain closed until 48 hours after the September 2026 unaudited results are filed with BSE, in line with SEBI requirements and the company’s insider-trading policy.

What did Accretion Nutraveda report for FY26?

Accretion Nutraveda reported FY26 revenue from operations of ₹33.60 crore and net profit after tax of ₹5.07 crore. Revenue was stated at ₹3,360.31 lakh, compared with ₹1,600.18 lakh in FY25, representing year-on-year growth of 110%.

EBITDA rose 87.94% to ₹7.01 crore in FY26 from ₹3.65 crore a year earlier. Net profit increased from ₹2.50 crore in FY25 to ₹5.07 crore, while earnings per share rose to ₹9.35 from ₹6.88. The reported EBITDA margin was 20.85%, compared with 22.79% in the prior year.

The available annual-results table separately lists FY26 revenue at ₹33.71 crore. The detailed revenue-from-operations figure of ₹33.60 crore is used here because it is accompanied by the stated year-on-year comparison and underlying lakh-denominated amount. The source data therefore indicates a small difference between reported revenue presentations.

How did Accretion Nutraveda perform in recent half-year periods?

Accretion Nutraveda recorded sales of ₹19.54 crore in the half year ended March 2026, compared with ₹14.06 crore in the half year ended September 2025. Operating profit increased to ₹3.56 crore from ₹3.30 crore across those periods, according to the available standalone half-yearly data.

Net profit for the March 2026 half year was ₹2.69 crore, against ₹2.33 crore in the September 2025 half year. Profit before tax rose to ₹3.30 crore from ₹2.87 crore. However, operating profit margin declined to 18.22% from 23.47%, while interest expense was largely stable at ₹0.27 crore against ₹0.26 crore.

The March 2025 half-year figures show sales of ₹10.85 crore, operating profit of ₹2.58 crore and net profit of ₹1.72 crore. This sequence shows that reported sales and profits increased through the disclosed periods, although operating margins in the March 2026 period were lower than the two preceding periods shown in the data.

What does the upcoming result mean for investors and operations?

The September 2026 result will provide the first disclosed view of Accretion Nutraveda’s performance in the current financial year after the FY26 expansion in revenue and profit. Investors will have updated figures for sales, operating profit, net profit, margins and earnings after the board approves the unaudited half-yearly accounts.

The company operates as an Ahmedabad-based contract development and manufacturing organisation serving Ayurvedic and nutraceutical segments. Its FY26 results indicated significant growth in revenue and EBITDA, but the lower EBITDA margin means the September disclosure will also be relevant for assessing whether profitability ratios changed during the first half of FY27.

A major corporate event during FY26 was Accretion Nutraveda’s BSE SME initial public offering. The company raised ₹24.77 crore through the allotment of 19.20 lakh equity shares at ₹129 per share. The provided information states that the IPO improved liquidity and reduced the debt-equity ratio to 0.12.

The scheduled meeting itself does not disclose the September financial outcome. It establishes the date on which the board is expected to review and approve the figures, after which the company is expected to file the results with BSE.

How has Accretion Nutraveda’s financial position changed?

Accretion Nutraveda’s reported financial scale has increased materially over the past four financial years. Annual revenue rose from ₹3.07 crore in FY23 to ₹5.20 crore in FY24, ₹16.01 crore in FY25 and ₹33.71 crore in FY26, based on the annual-results table.

Annual net profit increased from ₹0.28 crore in FY23 to ₹0.82 crore in FY24, ₹2.50 crore in FY25 and ₹5.07 crore in FY26. EBITDA increased from ₹0.79 crore in FY23 to ₹1.41 crore in FY24, ₹3.72 crore in FY25 and ₹7.00 crore in FY26. These reported figures provide the background against which the forthcoming September 2026 results will be assessed.

Conclusion

Accretion Nutraveda’s October 31 board meeting is significant because it will release the next financial update after a year in which revenue from operations reached ₹33.60 crore and net profit rose to ₹5.07 crore. The company’s disclosed half-year data also show growth in sales and profit, alongside a reduction in operating margin in the March 2026 period.

The immediate item to watch is the filing of unaudited results for the half year ended September 30, 2026, following the October 31 board meeting. The results will clarify the company’s first-half sales, profitability and margin position, while the trading window is scheduled to reopen 48 hours after the filing with BSE.